# US 6,727,280 B2 · Method for treating colorectal carcinoma using a taxane/tocopherol formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,280 B2
- Document ID: US6727280B2
- Status: Granted
- Kind: B2
- Application number: 10/188,289
- Filed: 2002-07-01
- Published: 2003-05-08
- Granted: 2004-04-27
- Earliest claimed: 1997-01-07
- Assignees: Sonus Pharmaceuticals, Inc.
- Inventors: Nagesh Palepu; Dean Kessler; Alexander K. Tustian; Steven C. Quay; Panayiotis P. Constantinides; Karel J. Lambert
- Web page: https://patentgrep.com/patent/US6727280B2

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/4858: {Organic compounds}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods for administering a taxane composition for the treatment of cancer. In one aspect, the compositions are not diluted prior to administration. Some embodiments provide methods for administering a taxane as a bolus injection or an intravenous infusion in less than about 30 minutes. In other aspects, the invention provides methods for administering a taxane to provide high concentrations of the taxane in blood or in tumors. Another aspect provides methods for administering a taxane to provide anti-tumor activities against solid tumors. In some embodiments, the methods provide anti-tumor activities against tumors that were resistant to conventional taxane administration methods. In some embodiments, the methods provide anti-tumor activities against colorectal tumors.

## Claims

### Claim 1

A method for treating a subject suffering from a colorectal carcinoma, comprising:
administering to a subject suffering from a colorectal carcinoma a therapeutically effective amount of a pharmaceutical composition comprising a taxane and a tocopherol.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administration provides anti-tumor activity.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tumor was taxane-resistant prior to the administration of the composition.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is administered in less than about 30 minutes.

### Claim 5 (depends on 1)

The method of claim 1, wherein the taxane is administered at a dose in the range from about 15 mg/m2 to about 225 mg/m2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the taxane is administered at a dose in the range from about 40 mg/m2 to about 120 mg/m2.

### Claim 7 (depends on 1)

The method of claim 1, wherein the taxane is administered once every three weeks.

### Claim 8 (depends on 1)

The method of claim 1, wherein the taxane is administered once every two weeks.

### Claim 9 (depends on 1)

The method of claim 1, wherein the taxane is administered weekly.

### Claim 10 (depends on 1)

The method of claim 1, wherein the taxane is administered twice a week.

### Claim 11 (depends on 1)

The method of claim 1, wherein the taxane is administered daily.

### Claim 12 (depends on 1)

The method of claim 1, wherein the taxane is paclitaxel.

### Claim 13 (depends on 12)

The method of claim 12, wherein the concentration of the paclitaxel in the composition is about 10 mg/ml.

### Claim 14 (depends on 1)

The method of claim 1, wherein the composition further comprises at least one of a tocopherol polyethylene glycol derivative, polyethylene glycol, or a polyoxypropylene-polyoxyethylene glycol nonionic block co-polymer.

### Claim 15

A method for treating a subject suffering from a taxane-resistant colorectal carcinoma, comprising:
administering to a subject suffering from a taxane-resistant colorectal carcinoma a therapeutically effective amount of a pharmaceutical composition comprising a taxane and a tocopherol, wherein the tumor was taxane-resistant prior to the treatment with the composition.

### Claim 16 (depends on 15)

The method of claim 15, wherein the composition is administered in less than about 30 minutes.

### Claim 17 (depends on 15)

The method of claim 15, wherein the taxane is administered at a dose in the range from about 15 mg/m2 to about 225 mg/m2.

### Claim 18 (depends on 15)

The method of claim 15, wherein the taxane is administered at a dose in the range from about 40 mg/m2 to about 120 mg/m2.

### Claim 19 (depends on 15)

The method of claim 15, wherein the taxane is administered once every three weeks.

### Claim 20 (depends on 15)

The method of claim 15, wherein the taxane is administered once every two weeks.

### Claim 21 (depends on 15)

The method of claim 15, wherein the taxane is administered weekly.

### Claim 22 (depends on 15)

The method of claim 15, wherein the taxane is administered twice a week.

### Claim 23 (depends on 15)

The method of claim 15, wherein the taxane is administered daily.

### Claim 24 (depends on 15)

The method of claim 15, wherein the taxane is paclitaxel.

### Claim 25 (depends on 24)

The method of claim 24, wherein the concentration of the paclitaxel in the composition is about 10 mg/ml.

### Claim 26 (depends on 15)

The method of claim 15, wherein the composition further comprises at least one of a tocopherol polyethylene glycol derivative, polyethylene glycol, or a polyoxypropylene-polyoxyethylene glycol nonionic block co-polymer.

### Claim 27

A method for treating a subject suffering from a colorectal carcinoma resistant to a paclitaxel composition comprising polyoxyethylated castor oil and ethanol, comprising:
administering to a subject suffering from a colorectal carcinoma resistant to a paclitaxel composition comprising polyoxyethylated castor oil and ethanol, a therapeutically effective amount of a pharmaceutical composition comprising a taxane and a tocopherol, wherein the tumor was taxane-resistant prior to the treatment with the composition.

### Claim 28

A method for treating a subject suffering from a colorectal carcinoma, comprising:
administering to a subject suffering from a colorectal carcinoma a therapeutically effective amount of a pharmaceutical composition comprising paclitaxel, a tocopherol, and a tocopherol polyethylene glycol derivative.

### Claim 29 (depends on 28)

The method of claim 28, wherein the administration provides anti-tumor activity.

### Claim 30 (depends on 28)

The method of claim 28, wherein the tumor was taxane-resistant prior to the administration of the composition.

### Claim 31 (depends on 28)

The method of claim 28, wherein the composition is administered in less than about 30 minutes.

### Claim 32 (depends on 28)

The method of claim 28, wherein the paclitaxel is administered at a dose in the range from about 15 mg/m2 to about 225 mg/m2.

### Claim 33 (depends on 28)

The method of claim 28, wherein the paclitaxel is administered at a dose in the range from about 40 mg/m2 to about 120 mg/m2.

### Claim 34 (depends on 28)

The method of claim 28, wherein the composition is administered once every three weeks.

### Claim 35 (depends on 28)

The method of claim 28, wherein the composition is administered once every two weeks.

### Claim 36 (depends on 28)

The method of claim 28, wherein the composition is administered weekly.

### Claim 37 (depends on 28)

The method of claim 28, wherein the composition is administered twice a week.

### Claim 38 (depends on 28)

The method of claim 28, wherein the composition is administered daily.

### Claim 39 (depends on 28)

The method of claim 28, wherein the concentration of the paclitaxel in the composition is about 10 mg/ml.

### Claim 40 (depends on 28)

The method of claim 28, wherein the composition further comprises at least one of polyethylene glycol, or a polyoxypropylene-polyoxyethylene glycol nonionic block co-polymer.

### Claim 41

A method for treating a subject suffering from a colorectal carcinoma, comprising:
administering to a subject suffering from a colorectal carcinoma a therapeutically effective amount of a pharmaceutical composition comprising a taxane; α-tocopherol; a tocopherol polyethylene glycol succinate; and an aqueous phase; wherein the composition is an emulsion or a microemulsion having an oil and a water phase, and wherein all of the taxane is in the oil phase.

### Claim 42 (depends on 41)

The method of claim 41, wherein the taxane is paclitaxel.
